1 / 24

Scleromyxedema

Scleromyxedema. UNC Morning Report December 16, 2009 Christine Williams, MD. SCLEROMYXEDEMA. Also called lichen myxedematosus scleromyxedema of Groton papular mucinosis Epidemiology: quite rare, largest case series 26 Average age 55 3:1 Female to male ratio.

benedict-mcleod
Download Presentation

Scleromyxedema

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Scleromyxedema UNC Morning Report December 16, 2009 Christine Williams, MD

  2. SCLEROMYXEDEMA • Also called • lichen myxedematosus • scleromyxedema of Groton • papular mucinosis • Epidemiology: quite rare, largest case series 26 • Average age 55 • 3:1 Female to male ratio

  3. PHYSICAL FINDINGS: Scleromyxedema • Flesh colored to yellow/red, papular skin eruption • Indurated with a cobblestone feel • Distribution includes head, posterior auricular area, neck, arms and trunk • Midportion of back can be involved • NOT involved in scleroderma • Sclerodactyly can be present but papular

  4. SKIN FINDINGS: Scleromyxedema

  5. SKIN FINDINGS: Scleromyxedema

  6. Associated Organ Involvement • Raynaud’s phenomenon • Esophageal dysmotility • Myopathy • Pulmonary hypertension has been reported • Neurologic symptoms • Encephalopathy, seizures, coma and psychosis

  7. LABORATORY DATA: Scleromyxedema • Monoclonal gammopathy with lambda chains • Level of paraprotein does not decrease after effective treatment • Pathogenesis unclear • Mucinous deposition throughout the dermis • Thick collagen bundles • Increased fibroblast-like cells • Inflammatory infiltrate • Autoimmune markers typically negative

  8. TREATMENT: Scleromyxedema • Variable immunosuppressants have been tried • IVIG 2g/kg monthly for 2-3 months then maintenance every 10-12 weeks • Melphalan • Cyclophosphamide • Cyclosporine • Thalidomide • Stem cell transplant has been used

  9. DIFFERENTIAL: IMMUNOLOGIC • Scleroderma • Obliterative vasculopathy, extensive collagen deposition and fibrosis • Eosinophilic fasciitis (Shulman’s syndrome) • GVHD • Lichen sclerosus et atrophicus • POEMS Syndrome • Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes • SLE, dermatomyositis overlap syndromes

  10. DIFFERENTIAL: METABOLIC/GENETIC • Porphyria cutanea tarda • Hypothyroidism (myxedema) • Phenylketonuria • Stiff skin syndrome • congenital facial dystrophy • Progeroid disorders • Progeria, acrogeria

  11. DIFFERENTIAL: DEPOSITION • Systemic amyloidosis • Nephrogenic systemic fibrosis • Scleredema adultorum • Lipodermatosclerosis

  12. DIFFERENTIAL: TOXIC/OCCUPATIONAL • Polyvinyl chloride • Organic solvents • Silica • Epoxy resins • Bleomycin • Pentazocine • Carbidopa • Eosinophilia-myalgiasydnrome (L-tryptophan) • Toxic-oil syndrome (aniline-denatured rapeseed oil) • Post-radiation fibrosis

  13. SCLERODERMA • 1-2:100,000 • Ages 30-50, more common in women • Diffuse cutaneous systemic sclerosis • Limited cutaneous systemic sclerosis • Calcinosis cutis • Raynaud’s phenomenon • Esophageal dysmotility • Sclerodactyly • Telangiectasia

  14. SCLERODERMA • Early in disease, arthralgias and soft tissue swelling may be more prominent • Heartburn/Dysphagia • DOE • Pulmonary HTN • Diarrhea w/malabsorption • Mucocutaneous telangiectasias • Digital infarctions • Hyperpigmentation • Calcinosis cutis • 10% do not have skin induration

  15. SCLERODERMA: Autoantibodiess • ANA screening (95% +) • Anti-PM-Scl • Increased risk of myositis • Anti-Scl 70 – DNA topoisomerase I (dcSSc) • Increased risk of interstitial lung disease • Anti-centromere (lcSSc) • Anti-U3-RNP • Increased risk of Pulmonary HTN and myositis • Anti-RNA polymerase III • Anti-B2 glycoprotein I • Increased risk of thromboembolism, macrovasculardz • Specific 99% • Not sensitive 20-50% • High titers of RF, anti-CCP, anti-U1 RNP, anti-dsDNA or anti-Smith uncommon. ANCA not associated with systemic sclerosis.

  16. Nephrogenic Systemic Fibrosis • History of renal failure and HD • Gadolinium exposure , high epo doses are associated • Rapidly developing, days to weeks • Confluent fibrotic skin induration ‘peaud’orange’  cobblestone • Nodular plaques which become woody • Tender, pruritic, burning • Brawny hyperpigmentation • Flexion contractures • Stocking/glove distribution, face usually spared • Muscles, myocardium, lungs, kidneys and testes • Fibroblast proliferation, thick collagen bundles and mucin deposition (very similar) but can extend into adipose and muscle layers • MRI – increased T1 signal in muscles, fascial and muscular edema • Rx-sodium thiosulfate?, imatinibmesylate, PT, pain management

  17. Nephrogenic Systemic Fibrosis

  18. Eosinophilic Fasciitis • Scleroderma-like painful skin lesionsof extremities (forearms/calves) • Hands and face usually spared • Hypergammaglobulinemia (polyclonal) • Eosinophilia • Dermal/hypodermal sclerosis w/fibrotic thickening of subcutaneous adipose septa, superficial fascia and perimysium • Epidermis spared • Flexion contractures and peripheral nerve compression can complicate • Synovitisand constitutional symptoms possible • 2:1 male: female ratio • Preceded by vigorous exercise or trauma in 50% • 10-15% have underlying hematologic d/o or malignancy • Associated with spirochetes • Similar to symptoms from • rapeseed oil (Toxic oil sydrome, Spain ‘81) • L-tryptophan (eosinophilia-myalgiasydrome, US ‘89) • Rx: Corticosteroids, PT

  19. Eosinophilic Fasciitis

  20. SCLEREDEMA(ScleredemaAdultorum/Buschke) • Deposition of collagen and mucin causing thickening of the dermis • Non-pitting, doughy or woody induration • Neck, back, interscapular region, face, chest • Associated with • Post-infectious (strep), occurs in children also [type 1] • Monclonalgammopathies [type 2] • Multiple myeloma IgG, IgA, MGUS, Waldenstrom’s • Poorly controlled DM [type 3] • Treatment - treat underlying disease • Immunosuppressants (steroids, MTX) w/o clear benefit • PUVA therapy, UVA-1 treatment

  21. SCLEREDEMA

  22. Proposed approach to differential • History for risk factors, exposure to gadolinium • Raynaud’s phenomenon • Skin distribution • Presence of neurologic disease • ANA • SPEP • Full-thickness skin biopsy

  23. REFERENCES • Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am. 2008 Feb;34(1):199-220; ix. • Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermotol. 2009 Jun;60(6):1027-41. Epub 2009 Feb 26. • Varge, J. Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate. Online. (utdol.com) Accessed 14 December 2009.

More Related